Stock Price Quote

NAGARJUNA DRUGS LTD.

NSE : NABSE : 530064ISIN CODE : INE254C01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
- Chairman - Managing Director
Registered Office

Address Survey No 273,274, 467 Temple Road Bonthapally Village Jinnaram Mandal,
Medak,
Andhra Pradesh-502313

Phone

Email --

Website NA

Registrars Details
Nagarjuna Drugs Ltd.
Survey No 273,274, 467 Temple Road Bonthapally Village Jinnaram Mandal,Medak
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Dec 00 ANNUAL 00
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26275.00 (0.70%)
M.Cap ( in Cr)55502.75
NGL Fine-Chem (BSE)
peergroup  2375.00 (4.89%)
M.Cap ( in Cr)1408.44
Neuland Laboratories (BSE)
peergroup  7605.90 (1.14%)
M.Cap ( in Cr)9745.33
Sanofi India (BSE)
peergroup  8474.40 (0.94%)
M.Cap ( in Cr)19641.90
Solara Active Pharma (BSE)
peergroup  486.20 (15.01%)
M.Cap ( in Cr)1763.28

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.